%0 Journal Article
%T 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors
%A Amy Barone
%A Ephraim Parent
%A Hayden Leeds
%A Jonathan McConathy
%A Joshua Rubin
%A Karen Gauvain
%A Manu Goyal
%A Maria Rosana Ponisio
%A Michael Grimaldi
%J Archive of "Neuro-Oncology Practice".
%D 2018
%R 10.1093/nop/npx008
%X Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using 18F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors
%K bevacizumab
%K FDOPA PET
%K monitoring response
%K pediatric brain tumors
%K recurrent brain tumors
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909807/